Higher Wegovy Dose Delivers Sustained 21% Weight Loss Independent of Early Response
New STEP UP trial results presented in Istanbul indicate Novo Nordisk’s 7.2 mg dose of Wegovy (semaglutide) produced an average 21% total body weight loss over 72 weeks in adults with obesity and without type 2 diabetes, regardless of whether patients were early responders. Secondary analyses show most weight loss was fat mass, with limited loss of…